Mosquito borne diseases like malaria, dengue, zika, chikungunya, yellow fever are spread by mosquito bites causing various symptoms ranging from mild fever to more severe illnesses. These diseases remain a major public health threat in tropical and subtropical regions. Treatment of mosquito borne diseases involves use of drugs like antimalarial, antiviral and antibiotics. Drug development for these diseases is challenging due to the complex life cycle of pathogens and vectors involved. However, various companies are undertaking initiatives involving product developments and partnerships to curb the burden of these diseases. 

The global Mosquito Borne Disease Treatment Market is estimated to be valued at Us$ 3.11 Bn in 2023 and is expected to exhibit a CAGR Of 6.5% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics

Increasing product launches and government support are major drivers for mosquito borne disease treatment market. One such driver being increasing product launches. Over the past decade, several pharmaceutical companies have stepped up efforts to develop novel drugs and vaccines against mosquito borne illnesses owing to their significant disease burden globally. For instance, in 2021, Pfizer received U.S FDA approval for its long-acting injectable mosquitocidal drug, RAPIVAB (peramivir) for treatment of acute uncomplicated influenza in patients aged 2 years and older. RAPIVAB demonstrated statistically significant efficacy against influenza compared to a placebo group in clinical trials and addressed the need for long-acting treatment options. In addition, governments across endemic regions are supporting product developments through partnerships and funding. For example, the U.S. National Institutes of Health (NIH) is funding multiple research projects aimed at developing vaccines and drugs against mosquito borne pathogens including Zika virus, dengue virus, chikungunya virus through public-private partnerships involving pharmaceutical companies and research institutes. Such initiatives are fueling pipeline developments and new product launches thereby driving the market growth over the forecast period.

SWOT Analysis

Strength: Mosquito borne diseases like malaria and dengue are a major public health concern globally which has increased the focus on research and development of preventive measures. Government initiatives to create awareness and spread knowledge regarding mosquito borne diseases have helped control the impact of such diseases. Availability of advanced diagnostic tools allow for rapid detection and monitoring of mosquito transmitted infections.

Weakness: Lack of healthcare infrastructure and resources in developing nations restrict widespread availability of treatment and preventive measures. Resistance to common drug regimens has reduced effectiveness of some medications against mosquito transmitted infections. Challenges remain in mosquito eradication efforts due to their ability to develop resistance.

Opportunity: Growth in funding for development of novel vaccines and drugs offers potential for more effective therapeutic interventions. Technologies focused on genetic engineering of mosquitoes can reduce mosquito populations over time. Rising awareness has increased demand for personal protective measures against mosquito bites.

Threats: Emergence of new pathogenic strains can reduce efficacy of existing treatments. Climate changes may alter mosquito habitats and transmission patterns for diseases. Economic slowdowns can affect healthcare spending and access to new diagnostics/treatments.

Key Takeaways

The Global Mosquito Borne Disease Market Demand is expected to witness high growth over the forecast period supported by rising disease burden, increasing research efforts and growing demand for preventive measures. The market in the Asia Pacific region currently dominates due to high endemicity of mosquito transmitted infections like malaria and dengue in many developing countries of the region. Countries like India, Indonesia and China account for a major share owing to their large population bases and tropical climates conducive for mosquito breeding.

Key players operating in the Mosquito Borne Disease market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Sanofi S.A., AbbVie Inc., and GlaxoSmithKline plc. These players are focused on developing novel drugs and vaccines through extensive research and clinical trials. Increasing collaboration between industry and academic institutes is also leading to newer treatment options.

Get more insights on this topic :

http://insightsmarket.weebly.com/blog/mosquito-borne-disease-market-is-estimated-to-witness-high-growth-owing-to-opportunity-of-expanding-patient-base